The DOI matches its Crossref record; 436 of the 436 references it cites were found in a registry or an index.
The amyloid cascade hypothesis: an updated critical review
Open accessAbstract
Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer’s disease have created excitement and have been heralded as corroboration of the amyloid cascade hypothesis. However, while Aβ may contribute to disease, genetic, clinical, imaging and biochemical data suggest a more complex aetiology. Here we review the history and weaknesses of the amyloid cascade hypothesis in view of the new evidence obtained from clinical trials of anti-amyloid antibodies. These trials indicate that the treatments have either no or uncertain clinical effect on cognition. Despite the importance of amyloid in the definition of Alzheimer’s disease, we argue that the data point to Aβ playing a minor aetiological role. We also discuss data suggesting that the concerted activity of many pathogenic factors contribute to Alzheimer’s disease and propose that evolving multi-factor disease models will better underpin the search for more effective strategies to treat the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 401–436 of 436
Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer’s Disease
Lao, K., Zhang, R., Luan, J., Zhang, Y., & Gou, X. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200851 · Cited by 25
Computing the Pathogenicity of Alzheimer’s Disease Presenilin 1 Mutations
Tang, N., Dehury, B., & Kepp, K. P. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00896 · Cited by 24
Self-citationAlzheimer’s disease: the controversial approval of Aducanumab
Tagliavini, F., Tiraboschi, P., & Federico, A. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05497-4 · Cited by 24
A quantitative model of human neurodegenerative diseases involving protein aggregation
Kepp, K. P. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.04.001 · Cited by 23
Self-citationUnblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials
Gleason, A. J., Ayton, S., & Bush, A. I. (2020) · European Journal of Neurology · doi:10.1111/ene.14484 · Cited by 23
Das, H. K., Tchedre, K. T., & Mueller, B. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07794.x · Cited by 22
Molecular Recipe for γ-Secretase Modulation from Computational Analysis of 60 Active Compounds
Tang, N., Somavarapu, A. K., & Kepp, K. P. (2018) · ACS Omega · doi:10.1021/acsomega.8b02196 · Cited by 22
Self-citationHøilund‐Carlsen, P. F., Revheim, M.-E. R., Alavi, A. A., Satyamurthy, N., & Barrio, J. R. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220841 · Cited by 22
Self-citationDominant negative mechanism of Presenilin-1 mutations in FAD
Watanabe, H., & Shen, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717180114 · Cited by 21
Computational analysis of Alzheimer-causing mutations in amyloid precursor protein and presenilin 1
Mehra, R., & Kepp, K. P. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108168 · Cited by 21
Self-citationThe Role of Presenilin in Protein Trafficking and Degradation—Implications for Metal Homeostasis
Greenough, M. A. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0826-4 · Cited by 20
Circular Inference in Dementia Diagnostics
Høilund‐Carlsen, P. F., Barrio, J. R., GJEDDE, A. H., Werner, T. J., & Alavi, A. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180050 · Cited by 20
Self-citationRobbins, J., Busquets, O., Tong, M., & de la Monte, S. M. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200238 · Cited by 20
Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain
Mahase, E. (2022) · BMJ · doi:10.1136/bmj.o2912 · Cited by 19
Donanemab removes Alzheimer's plaques: what is special about its target?
Alawode, D. O. T., Heslegrave, A., Fox, N. C., & Zetterberg, H. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00144-6 · Cited by 18
Scientists tie third clinical trial death to experimental Alzheimer’s drug
(2022) · AAAS Articles DO Group · doi:10.1126/science.adg4121 · Cited by 18
Structure-activity relationship of presenilin in γ-secretase-mediated intramembrane cleavage
Cai, T., & Tomita, T. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.02.006 · Cited by 16
An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease
Daly, T. P., Herrup, K., & Espay, A. J. (2022) · AJOB Neuroscience · doi:10.1080/21507740.2022.2129858 · Cited by 16
Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
Imbimbo, B. P., Lucca, U., & Watling, M. I. L. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000535 · Cited by 15
A Bayesian perspective on Biogen's aducanumab trial
Temp, A. G. M., Ly, A., van Doorn, J. B., Wagenmakers, E., Tang, Y., Lutz, M. W., & Teipel, S. J. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12615 · Cited by 14
Risk Factors for Alzheimer's Disease: An Overview for Clinical Practitioners
Kim, K. Y., Wood, B. E., & Wilson, M. I. (2005) · The Consultant Pharmacist · doi:10.4140/tcp.n.2005.224 · Cited by 13
Viglietta, V., O'Gorman, J. T., Williams, L. J., Tian, Y., Sandrock, A. W., Doody, R. S., Salloway, S., Barkhof, F., Vellas, B. J., Sano, M. C., et al. (2016) · Neurology · doi:10.1212/wnl.86.16_supplement.s1.003 · Cited by 13
Understanding familial Alzheimer's disease: The fit‐stay‐trim mechanism of γ‐secretase
Mehra, R., & Kepp, K. P. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1556 · Cited by 13
Self-citationA Bayesian Reanalysis of the Phase III Aducanumab (ADU) Trial
Costa, T., & Cauda, F. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220132 · Cited by 13
Aducanumab and the certainty of evidence
McCleery, J. M., & Quinn, T. J. (2021) · Age and Ageing · doi:10.1093/ageing/afab167 · Cited by 13
Risk factors for dementia of Alzheimer's type: A case-control, retrospective evaluation
Massaia, M., Ceva, A. P. D., Bo, M., Cappa, G., Zannella, P., Persico, D., Ferrario, E., & Fabris, F. M. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00146-7 · Cited by 11
Second death linked to potential antibody treatment for Alzheimer’s disease
(2022) · AAAS Articles DO Group · doi:10.1126/science.adf9701 · Cited by 11
Høilund‐Carlsen, P. F., Revheim, M.-E. R., & Alavi, A. A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220190 · Cited by 10
Self-citationYoon, Y., Voloudakis, G., Doran, N., Zhang, E., Dimovasili, C., Chen, L., Shao, Z., Darmanis, S., Tang, C. Y., Tang, J., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0812-7 · Cited by 9
Self-citationFDA's green light, science's red light
Perlmutter, J. S. (2021) · Science · doi:10.1126/science.abk0575 · Cited by 9
Of education and public policy: Aducanumab
Lundebjerg, N. E., Hollmann, P. A., & Supiano, M. A. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17523 · Cited by 9
Lythgoe, M., & Prasad, V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.012 · Cited by 8
Zimmer, J. A., Solomon, P. R., Evans, C. D., Lu, M., Sims, J. R., Brooks, D. A., & Mintun, M. A. (2022) · Neurology · doi:10.1212/wnl.98.18_supplement.1688 · Cited by 7
Prevention of Alzheimer's Disease and Other Dementias
Woodward, M. C. (2003) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr2003332138 · Cited by 6
Re: Aducanumab-Related ARIA: Paean or Lament?
Wassef, H. R., & Colletti, P. M. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004490 · Cited by 5
Overweight as a risk factor for dementia
Diaz, R. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.168 · Cited by 3
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“78,111,112 115 However, FAD mutations are not necessarily linked to an increase in A β 42 levels or an elevation of A β 42 /A β 40 ratio.”
BackgroundAnti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Kamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
Granzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
Self-citationOnce upon a time, the Amyloid Cascade Hypothesis
Granzotto, A., & Sensi, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102161 · Cited by 57
Self-citation
Metadata
- Authors
- Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-05-15
- Volume
- 146
- Issue
- 10
- Pages
- 3969-3990
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4376614794
- Cited by
- 284
- References
- 436
- FWCI
- 41.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.